The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000717358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/05/2026
Date registered
Help: Date registered
16/06/2026
Date last updated
Help: Date last updated
16/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
When heart tests are misleading: understanding false positive troponin results in patients suspected to have troponin assay interferences
Scientific title
Macrotroponin interference in Myocardial Infarction with non-obstructive coronary artery disease (MINOCA): Identification and Clinical impact in patients suspected to have troponin assay interferences
Additional trial identifiers [1] 317218 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Myocardial Infarction with non-obstructive coronary artery disease (MINOCA) 341827 0
Condition category
Condition code
Cardiovascular 337898 337898 0 0
Coronary heart disease
Public Health 337899 337899 0 0
Epidemiology

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
This study aims to systematically assess the prevalence, clinical and economic impacts of troponin assay interference i.e macrotroponin in patients with a presumed diagnosis of MINOCA and static troponin elevations.
This is a single-centre, prospective observational cohort study conducted at the Royal Melbourne Hospital.
Participants will be identified retrospectively via electronic medical record (EMR) and pathology database screening (2021–2027) and prospectively recalled for a single study visit involving confirmatory troponin testing and survey completion. The study does not involve any investigational treatment or alteration to standard clinical care.
Prospective recall with alternative troponin assay (Alinity Troponin I, Vitros Troponin I and Roche Troponin T) to test for interference. Polyethylene glycol (PEG) testing provides direct confirmation of macrotroponin to provide a precise prevalence estimate (primary aim). All blood samples will be collected in person at a Royal Melbourne Hospital outpatient pathology collection centre. Electronic medical record linkage will facilitate ascertainment of major adverse cardiovascular events (MACE), healthcare utilisation, and healthcare costs. Participants will complete the MacNew Quality of Life After Myocardial Infarction questionnaire, providing assessment of quality of life and psychological impact as secondary study outcomes. The questionnaire requires approximately 20 minutes to complete and can be administered via telehealth or through a secure REDCap platform according to participant preference. Blood samples will be collected and initially processed locally before undergoing batched laboratory analysis.. Roche high-sensitivity troponin T testing and PEG precipitation assays will be performed in batches rather than immediately following sample collection. Testing is anticipated to be completed in approximately two weeks, after which results will be reviewed and classified as consistent or inconsistent with macrotroponin interference.

Intervention code [1] 333995 0
Diagnosis / Prognosis
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345476 0
Prevalence of troponin assay interference in patients with static troponin elevation and non-obstructive coronary arteries
Timepoint [1] 345476 0
Baseline study visit (Day 0 blood collection) with confirmation testing performed on the same plasma sample obtained at enrolment
Secondary outcome [1] 461797 0
Clinical characteristics, downstream investigations, healthcare utilisation, and healthcare costs associated with troponin assay interference. This will be assessed as a composite outcome.
Timepoint [1] 461797 0
Baseline study visit, retrospective review of the index presentation, and longitudinal follow-up to 12 months following enrolment
Secondary outcome [2] 461798 0
Health-related quality of life and psychological impact associated with persistent unexplained troponin elevation. This will be assessed as a composite outcome.
Timepoint [2] 461798 0
Baseline study visit (Day 0) and follow-up visit at 8 to 14 days after result disclosure
Secondary outcome [3] 461799 0
Major adverse cardiovascular events
Timepoint [3] 461799 0
Twelve months following enrolment into the study

Eligibility
Key inclusion criteria
• Adults 18 years and over
• Non-dynamic troponin kinetics defined as less than 20% rise and fall
• Patients suspected to have troponin assay interferences
• Underwent invasive coronary angiography or CT coronary angiogram between 2021–2027 which revealed non-obstructive coronary artery disease (defined as <50% stenosis)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Previously confirmed assay interefences i.e macrotroponin
• Chronic kidney disease (CKD) stage 5
• Troponin elevation >50,000 ng/L
• Recent coronary revascularisation
• Significant coronary artery disease (CAD) medically managed due to comorbidities
• Arrhythmia-related myocardial infarction (MI)
• Type 2 MI from sepsis, pulmonary embolism and myocarditis, non-cardiac surgery.

Study design
Purpose
Duration
Selection
Timing
Statistical methods / analysis
This is a single-centre, prospective observational cohort study conducted at the Royal Melbourne Hospital.
Participants will be identified retrospectively via electronic medical record (EMR) and pathology database screening (2021–2027) and prospectively recalled for a single study visit involving confirmatory troponin testing and survey completion. The study does not involve any investigational treatment or alteration to standard clinical care.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29534 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment postcode(s) [1] 45855 0
3050 - Parkville

Funding & Sponsors
Funding source category [1] 321796 0
Hospital
Name [1] 321796 0
Royal Melbourne Hospital
Country [1] 321796 0
Australia
Primary sponsor type
Hospital
Name
Royal Melbourne Hospital
Address
Country
Australia
Secondary sponsor category [1] 324646 0
None
Name [1] 324646 0
Address [1] 324646 0
Country [1] 324646 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320340 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 320340 0
Ethics committee country [1] 320340 0
Australia
Date submitted for ethics approval [1] 320340 0
Approval date [1] 320340 0
17/03/2026
Ethics approval number [1] 320340 0
HREC/125113/MH-2026

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150146 0
Dr Anoop Koshy
Address 150146 0
Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050
Country 150146 0
Australia
Phone 150146 0
+61 3 9342 7589
Fax 150146 0
Email 150146 0
Contact person for public queries
Name 150147 0
Dr Lung En (Marcus) Teng
Address 150147 0
Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050
Country 150147 0
Australia
Phone 150147 0
+61 3 9342 7589
Fax 150147 0
Email 150147 0
Contact person for scientific queries
Name 150148 0
Dr Lung En (Marcus) Teng
Address 150148 0
Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050
Country 150148 0
Australia
Phone 150148 0
+610431951177
Fax 150148 0
Email 150148 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.